Smith Hunter C 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Rhythm Pharmaceuticals (RYTM) CFO Hunter C. Smith Sells 7,954 Shares
What Happened
- Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, sold a total of 7,954 common shares in open‑market transactions. The sales occurred on February 17 and February 19, 2026, for aggregate proceeds of approximately $805,814.
- Breakdown by trade (date — shares — weighted‑avg price — proceeds): Feb 17 — 1,200 @ $99.42 = $119,298; 200 @ $100.52 = $20,104; 900 @ $101.70 = $91,530; 1,069 @ $103.00 = $110,110; 200 @ $103.84 = $20,768. Feb 19 — 1,308 @ $100.27 = $131,153; 1,692 @ $100.92 = $170,755; 800 @ $102.10 = $81,676; 585 @ $103.28 = $60,420.
- This was a sale (not a purchase or option exercise). The transactions were effected under an established Rule 10b5‑1 trading plan.
Key Details
- Transaction dates: February 17 and February 19, 2026. Filing date: February 19, 2026 (filed within the typical two‑business‑day Form 4 deadline).
- Total shares sold: 7,954. Total proceeds: ~$805,814.
- Reported prices are weighted averages; the filing’s footnotes show the actual trades occurred across price ranges roughly from $99.25 to $103.50 per share.
- Notable footnote: the sales were made pursuant to a Rule 10b5‑1 plan adopted February 28, 2025 (pre‑arranged trading plan).
- Shares owned after the transaction: not provided in the excerpt supplied here (refer to the full Form 4 for the reporter’s post‑trade holdings).
Context
- A 10b5‑1 plan indicates these sales were pre‑planned and may be routine (e.g., for diversification or liquidity) rather than a spontaneous statement about company prospects. That said, sales by executives reduce their stake but do not, by themselves, prove a change in view.
- For retail investors, purchases typically carry more direct signaling value than routine, prearranged sales; use insider activity as one data point alongside company fundamentals and news.
Insider Transaction Report
Form 4
Smith Hunter C
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-17$99.42/sh−1,200$119,298→ 117,266 total - Sale
Common Stock
[F1][F3]2026-02-17$100.52/sh−200$20,104→ 117,066 total - Sale
Common Stock
[F1][F4]2026-02-17$101.70/sh−900$91,530→ 116,166 total - Sale
Common Stock
[F1][F5]2026-02-17$103.00/sh−1,069$110,110→ 115,097 total - Sale
Common Stock
[F1]2026-02-17$103.84/sh−200$20,768→ 114,897 total - Sale
Common Stock
[F1][F6]2026-02-19$100.27/sh−1,308$131,153→ 113,589 total - Sale
Common Stock
[F1][F7]2026-02-19$100.92/sh−1,692$170,755→ 111,897 total - Sale
Common Stock
[F1][F8]2026-02-19$102.10/sh−800$81,676→ 111,097 total - Sale
Common Stock
[F1][F9]2026-02-19$103.28/sh−585$60,420→ 110,512 total
Footnotes (9)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith|2026-02-19